£2.2M
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
Oxford Drug Design
Oxford Drug Design develops novel cancer therapeutics using a proprietary computational and machine learning platform.
£4.4MTotal raised
Oxford Drug Design is a biotechnology company that uses a proprietary computational and machine learning platform to discover small-molecule drugs for oncology. The firm originated as a spinout from Oxford University.
Categories
Team
PF
Paul Finn
CEO
Paul brings extensive drug design and research experience from leadership roles at Oxford Drug Design, InhibOx, and TopoTarget A/S. He also serves as a professorial research fellow at the University of Buckingham.
LinkedInGR
Graham Richards
Professor
Graham brings scientific and academic experience from the University of Oxford, alongside founding and chairing roles across multiple life sciences and technology ventures.
LinkedInAR
Alan Roth
CEO
Investors
- £2.2M
- £2.2M
Funding history
£2.2M
The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.